Genes · 2021 · 21 citations · 29 references
MedicineMolecular GeneticsOncologyEpigeneticsGene ExpressionMolecular OncologyCancer BiomarkersCancer EpigeneticsColorectal CancerEpigenetic Alterations In CancerMolecular Classification Of TumorsNoncoding Rna In CancerCancer Epigenetic BiomarkersCancer Subtype DiscoveryColorectal Cancer PrognosisLong Non-coding Ribonucleic AcidsLong Noncoding Rna RegulationN6-methyladenosine RegulationNoncoding Rna Expression ProfilingPrognostic Rna Biomarkers
BACKGROUND: The N6-methyladenosine (m6A) RNA modification can modify long non-coding RNAs (lncRNAs), thereby affecting the tumorigenesis and progression of tumors. However, the underlying role of m6A-modified lncRNAs in colorectal cancer (CRC) remains largely unknown. Therefore, our aim was to assess the prognostic value of m6A-modified lncRNAs in CRC patients. METHODS: The gene expression and clinicopathological data of CRC were extracted from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was used to investigate the m6A-modified lncRNAs. Consensus clustering was conducted to identify molecular subtypes of CRC, and the clinical significance of molecular subtypes was identified. The least absolute shrinkage and selection operator analysis (LASSO) was applied to establish a risk signature. Finally, a prognostic nomogram with risk score and clinicopathological variables was established. RESULTS: In total, 29 m6A-modified lncRNAs were identified as prognostic lncRNAs. Two molecular clusters were identified and significant differences were found with respect to clinicopathological features and prognosis. Cluster1 is associated with poor overall survival (OS), down-regulation of Programmed cell death ligand-1 (PD-L1) expression, lower immune score, and less immune cell infiltration. Then, an m6A-modified lncRNA signature for predicting OS was constructed in the TCGA training cohort. The signature demonstrated favorable prediction performance in both training and validation sets. Compared with low-risk patients, patients with high risk showed worse clinical outcomes, lower immune scores, and downregulated PD-L1 expression. Further analysis indicated that the signature was an independent prognostic indicator, and then a prognostic nomogram based on risk score, tumor location, and tumor stage was established. CONCLUSIONS: Our study identified a seven m6A-modified lncRNA signature and established a prognostic nomogram that reliably predicts OS in CRC. These findings may improve the understanding of m6A modifications in CRC and provide insights into the prognosis and treatment strategy of CRC.
29
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman, Chih Long Liu, Michael R. Green et al. · Nature Methods · 2015 · 14.1K citations · Full text
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications · 2013 · 10.7K citations · Full text
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Kate D. Meyer, Yogesh Saletore, Paul Zumbo et al. · Cell · 2012 · 4.3K citations · Full text
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
Eliza Yankova, Wesley Blackaby, Mark R. Albertella et al. · Nature · 2021 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +13